• Fragment-based hit identification: thinking in 3D.

      Morley, A; Pugliese, A; Birchall, K; Bower, J; Brennan, P; Brown, N; Chapman, T; Drysdale, M; Gilbert, I; Hoelder, S; et al. (2013-12)
      The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.